Abrocitinib
Sign in to save this workspacePrimary targets: JAK1 · FDA status: FDA Approved
Selectivity scorecard
KISS
99.50
Gini
0.581
CATDS
0.024
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Abrocitinib. Strongest target: JAK1 at 98.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | JAK1 | 98.7% | 1.3% |
| 2 | JAK2 | 92.6% | 7.4% |
| 3 | TYK2 | 89.9% | 10.1% |
| 4 | LRRK2 | 62.1% | 37.9% |
| 5 | DMPK2 | 57.3% | 42.7% |
| 6 | AURORA_A | 55.6% | 44.4% |
| 7 | AURORA_C | 54.5% | 45.5% |
| 8 | JAK3 | 51.1% | 48.9% |
| 9 | MYLK4 | 50.0% | 50.0% |
| 10 | SRPK1 | 47.9% | 52.1% |
| 11 | STK38_NDR1 | 47.7% | 52.3% |
| 12 | PKA | 37.8% | 62.2% |
| 13 | BMPR2 | 35.8% | 64.2% |
| 14 | PKACB | 34.8% | 65.2% |
| 15 | TAK1 | 34.7% | 65.3% |
| 16 | FLT3 | 33.2% | 66.8% |
| 17 | MARK4 | 32.8% | 67.2% |
| 18 | CLK1 | 32.1% | 67.9% |
| 19 | MEK1 | 31.8% | 68.2% |
| 20 | RET | 31.3% | 68.7% |
Selectivity landscape
Where Abrocitinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Abrocitinib.
Annotations
Sign in to read and post annotations.
Loading…